Amgen taps Syapse’s learning health network to accelerate precision oncology

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JONGHO SHIN)
(Image: Getty/JONGHO SHIN)

Related tags: EHR, Real world evidence, Learning health network, Precision medicine, Oncology, Amgen

Amgen is collaborating with Syapse to support clinical trial enrollment and accelerated drug development using real-world evidence-based insights.

Formed in 2010, Syapse’s services enable health care providers to implement precision medicine through its software platform, data sharing network, and industry partnerships.

A Syapse spokesperson told us the recently announced collaboration with Amgen is focused on developing evidence of clinical utility that can be used to develop molecularly-targeted cancer treatments more quickly, and to ensure access to a more diverse patient group.

“The collaboration will also create opportunities for physicians and researchers to access analytic tools, real-world evidence-based insights, and collaborative research opportunities,”​ they said.

Syapse’s global provider-driven network of health systems captures data from electronic health records (EHRs), molecular testing results, and other sources, according to the company.

Leveraging this “learning health network,”​ the collaboration will help identify potential participants for Amgen-sponsored clinical trials at community health systems.

“Real-world evidence presents an exciting opportunity and collaborations such as this one are important because they bring together all the precision medicine stakeholders around the shared mission of getting targeted therapies to the right patients faster,” ​the spokesperson added.

Last year, Syapse teamed up with Medidata​ to develop a new suite of solutions, which aims to address precision medicine challenges and accelerate clinical research in oncology for trial sponsors

Related topics: Clinical Development

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars